The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2022 | Event-free survival results from CheckMate 816
David Paul Carbone, MD, PhD, Ohio State University, Columbus, OH, discusses the event-free survival (EFS) results from the CheckMate-816 trial (NCT02998528), which investigated nivolumab plus ipilimumab or chemotherapy with chemotherapy alone in a neoadjuvant setting for patients with early non-small cell lung cancer (NSCLC). The primary endpoints for the study were EFS (up to 69 months) and pathological complete response (pCR) at time of surgery. Patients who received nivolumab plus chemotherapy achieved a median EFS of 31.6 months, whereas patients receiving chemotherapy alone achieved a median PFS of 20.8 months. pCR was achieved by 24% of patients receiving neoadjuvant nivolumab plus chemotherapy, compared to 2.2% of patients receiving chemotherapy alone. The results from the CheckMate-816 trial led to approval by the FDA in March 2022 of nivolumab plus chemotherapy in this setting. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA
